Lipid Nanoparticle Team receives 2022 Governor General’s Innovation Award
The Rideau Hall Foundation (RHF) today announced the recipients of the seventh annual Governor General’s Innovation Awards (GGIA). Among the awardees was the team responsible for developing the lipid nanoparticles that delivered mRNA vaccines during the COVID-19 Pandemic. Dr. Pieter Cullis, Dr. Michael Hope, and Dr. Thomas Madden were nominated by the Canadian Institutes for […]
Dr. Pieter Cullis awarded Camurus Lipid Science Prize
Lipid Science Prize awarded to inventors of m-RNA and lipid nanoparticle technologies Dr. Katalin Karikó (University of Pennsylvania, BioNTech) and Dr. Pieter Cullis (University of British Columbia) were awarded the 2021 and 2022 Lipid Science Prize on April 4 by the independent research foundation Camurus Lipid Research Foundation at a symposium and prize ceremony in […]
Dr. Pieter Cullis named 2022 Canada Gairdner Award laureate
Award recognizes contributions to foundational technologies for COVID-19 mRNA vaccines Former LSI Director Dr. Pieter Cullis has been named a 2022 Canada Gairdner International Award laureate for his pioneering work developing the lipid nanoparticle delivery technology that enables mRNA therapeutics such as the highly effective COVID-19 mRNA vaccines. The Gairdner Awards annually recognize scientists whose […]
Dr. Pieter Cullis featured in Nature story on pivotal contributions to mRNA vaccines for COVID-19
“The tangled history of mRNA vaccines,” a news feature published today in Nature, reflects on the culmination of work by hundreds of scientists who worked on mRNA vaccines for decades before the coronavirus pandemic brought a breakthrough. Former LSI Director Pieter Cullis is featured for his linchpin contributions in lipid nanoparticles (LNPs). “Many experts highlight […]
Dr. Pieter Cullis talks lipid nanoparticles and vaccines of the future on CBC Radio’s Quirks & Quarks
Every week, more Canadians are rolling up their sleeves to get the shot that will protect them against COVID-19. One of the breakout vaccine technologies of this pandemic are the mRNA vaccines developed by Pfizer-BioNtech and Moderna. Those were some of the earliest vaccines out of the gate because of how easy they are to […]
LSI spinoff company the source of technology Pfizer’s mRNA COVID-19 vaccine ‘can’t work without’
The messenger RNA (mRNA)-based vaccine seen as a potential light at the end of the pandemic tunnel relies on innovations developed by an LSI spinoff, Acuitas Therapeutics. Now a highly successful biotech company, Acuitas contributed the lipid nanoparticle (LNP) delivery system to the COVID-19 vaccine candidate that is said to be 90 percent effective in […]
Prime Minister announces LSI spinoff to receive funding to develop an RNA Vaccine for COVID-19
Canada’s Prime Minister, Justin Trudeau, announced October 23 that Precision NanoSystems (PNI) will receive $18.2 Million from the Government of Canada to Develop an RNA Vaccine for COVID-19. PNI, which specializes in self-amplifying mRNA vectors, lipid-based drug delivery systems and nanomedicine manufacturing, will use the investment to advance a best-in-class, made-in-Canada vaccine. “An effective vaccine […]